Green Cross
VC Fund
Yongin, South Korea
Green Cross is a VC fund in Yongin focused on Health Care and Biotechnology. Green Cross continues to build on a long legacy of providing life-saving and life-sustaining specialty therapeutics. Their bioscience division began its business in 1971 as producing plasma-derived biotherapies for the first time in Korea. For more than 40 years, they have specialized in providing biotherapeutics to improve the quality of life forpeople with rare and serious diseases worldwide. Their vaccine business develops and produces paediatric and adult vaccine against a broad range of infectious diseases, from world’s 3rd hepatitis B vaccine to quadrivalent influenza vaccine.With their mission to improve health and well-being of people around the world, they have gone down a path that nobody wishes to explore. Their extensive research and development of innovative medicines that support treatment and prevention as well as cures for diseases in a wide range of therapeutic areas demonstrate their ongoing commitment to all people who rely on their products.
- Total investments:
- 8
- Last investment:
- Lead investor:
- 13%
Last updated:
For AI agents: llms.txt
Industries Green Cross invests in
Stages Green Cross invests in
Countries Green Cross invests in
Investment Focus
Industry
- Health Care 5 (63%)
- Biotechnology 4 (50%)
- Life Science 3 (38%)
- Medical 2 (25%)
- Therapeutics 2 (25%)
Stage
- Series B 5 (63%)
- Seed 1 (13%)
- Series C 1 (13%)
- Series E 1 (13%)
Country
- South Korea 4 (50%)
- United States 3 (38%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Kanaph Therapeutics
|
Kanaph Therapeutics is a biotech with activities that range from drug discovery to early-stage clinical trials. We are dedicated to developing next-generation therapeutics for oncology and autoimmune diseases. Our oncology pipeline includes bi-specific antibodies and small molecules that have a greatly enhanced immuno-stimulatory activity in thetumor microenvironment (TME) for efficient tumor eradication. Our autoimmune disease pipeline is composed of bispecific Fc-fusions that inhibit the alternative complement pathway while inhibiting angiogenesis and downstream complement activation as well. | $17.8M / Series C / Dec 27, 2023 | |
|
Kanaph Therapeutics
|
Kanaph Therapeutics is a biotech with activities that range from drug discovery to early-stage clinical trials. We are dedicated to developing next-generation therapeutics for oncology and autoimmune diseases. Our oncology pipeline includes bi-specific antibodies and small molecules that have a greatly enhanced immuno-stimulatory activity in thetumor microenvironment (TME) for efficient tumor eradication. Our autoimmune disease pipeline is composed of bispecific Fc-fusions that inhibit the alternative complement pathway while inhibiting angiogenesis and downstream complement activation as well. | $21M / Series B / Oct 12, 2020 | |
GeneCast
|
GeneCast develops liquid biopsy–based cancer diagnostics using its ADPS technology platform. The company focuses on detecting cancer-related genetic mutations from blood samples, enabling early detection and ongoing monitoring of disease progression. Its molecular testing solutions aim to support more accurate and less invasive cancer analysis forclinical use in oncology. | $12M / Series B / Jun 08, 2020 | |
Doing Lab
|
DoingLAB is a mobile dietary application featuring an artificial intelligence camera that can calculate calories via photograph. | $1.6M / Seed / May 31, 2020 | |
Vuno
|
Vuno offers artificial intelligence-based medical solutions for doctors and patients that provides a platform and consulting services for medical data analysis.Vuno develops automatic algorithm against various problems that occurs in medical sites as well as it develops diagnostic and quantification assisting software. The clients of the companyare Asan Medical Center and HYUNDAI. The company offers VunoMed that provides different forms of data analyzation for medical videos, ECGs, brain waves, and EMR data.Vuno is located in South Korea and the company was founded in 2014 by Yeha Lee, Kyu-Hwan Jung, and Dannis Kim. | $12M / Series B / Nov 20, 2018 | |
Genoplan
|
Genoplan provides customized products and services using biotechnology (BT) and information technology (IT). Genoplan is leading the way to create a world where everyone can use their genetic information.Best Company for Customized Genetic Service: Genoplan tells your genetic predisposition in an easy way. The algorithms developed by Genoplanhelp companies plan their customized services and products. Reasons for DNA Analysis: The DNA does not change for the rest of my life. In order to plan a healthier life, it is necessary to identify genetic information in advance and understand my tendency properly. Companies can offer personalized benefits to customers who want better lives. This will be a new competitive power than has never existed before.With the Best R&D Team: The Genoplan R&D team is made up of leading experts in biotechnology. Since its establishment, we have accumulated the greatest know-how by concentrating only on analysis of individual DNA. The entire analysis is conducted using state-of-the-art automated facilities, providing the fastest and the most accurate DNA analysis results. | $1M / Series B / Nov 20, 2018 | |
Juventas Therapeutics
|
Juventas Therapeutics is a privately-held clinical-stage biotechnology company developing a pipeline of regenerative therapies to treat life–threatening diseases. Founded in 2007 with an exclusive license from the Cleveland Clinic, Juventas has transitioned its therapeutic platform from concept to initiation of mid-stage clinical trials.Investors include Triathlon Medical Venture Partners, Early Stage Partners, Fletcher Spaght Ventures, Reservoir Venture Partners, North Coast Angel Fund, X Gen Ltd., JumpStart Inc., and Blue Chip Venture Co. The company has received nondilutive grant support through the Ohio Third Frontier funded Cleveland Clinic Ohio BioValidation Fund, Global Cardiovascular Innovation Center and Center for Stem Cell & Regenerative Medicine. | $13.5M / Series B / May 12, 2015 | |
Argos Therapeutics
|
Argos Therapeutics, Inc., a biotechnology company, engages in developing immunotherapy treatments for cancer, infectious and autoimmune diseases, and transplantation rejection. The company has clinical trial programs in cancer and human immunodeficiency virus. Its products include AGS-0031 for metastatic renal cell carcinoma; AGS-0041 for HIV; CD83soluble protein for transplant rejection/autoimmune disorders; Anti IFN-alpha monoclonal antibody2 for lupus; and regulatory T cell therapy3 for autoimmune disorders. The company was formerly known as MERIX Bioscience, Inc. Argos Therapeutics was founded in 1997 and is based in Durham, North Carolina. | $17.5M / Series E / Nov 20, 2013 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Green Cross invest in?
Green Cross invests primarily in Health Care, Biotechnology and Life Science startups, most often at Series B and Seed stage. Most of the 8 investments tracked by Shizune back companies in South Korea. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Green Cross last invest?
The most recent investment recorded for Green Cross closed in Dec 2023. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
